CovidChloroV1, Main, Exploration, bibRecord, 000848

Chloroquine paradox may cause more damage than help fight COVID-19.

Identifieur interne : 000848 ( Main/Exploration ); précédent : 000847; suivant : 000849

Chloroquine paradox may cause more damage than help fight COVID-19.

Auteurs : Anuj Sharma [États-Unis]

Source :

Microbes and infection [ 1769-714X ]

RBID : pubmed:32305500

Descripteurs français

KwdFr :
- Antipaludiques (effets indésirables), Antipaludiques (usage thérapeutique), Betacoronavirus (MeSH), Chloroquine (effets indésirables), Chloroquine (usage thérapeutique), Humains (MeSH), Infections à coronavirus (traitement médicamenteux), Pandémies (MeSH), Pneumopathie virale (traitement médicamenteux).
MESH :
- effets indésirables : Antipaludiques, Chloroquine.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Antipaludiques, Chloroquine.
- Betacoronavirus, Humains, Pandémies.

English descriptors

KwdEn :
- Antimalarials (adverse effects), Antimalarials (therapeutic use), Betacoronavirus (MeSH), COVID-19 (MeSH), Chloroquine (adverse effects), Chloroquine (therapeutic use), Coronavirus Infections (drug therapy), Humans (MeSH), Pandemics (MeSH), Pneumonia, Viral (drug therapy), SARS-CoV-2 (MeSH).
MESH :
- chemical , adverse effects : Antimalarials, Chloroquine.
- chemical , therapeutic use : Antimalarials, Chloroquine.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- Betacoronavirus, COVID-19, Humans, Pandemics, SARS-CoV-2.

Abstract

Novel coronavirus disease 2019 (COVID-19) pandemic is the most recent health care crisis without specific prophylactic or therapeutic drugs. Antimalarial drug chloroquine (CHL) and its safer derivative hydroxychloroquine (HCHL) have been proposed to be repurposed to treat SARS coronavirus-2 (SARS-CoV-2), the causative agent of COVID-19. CHL/HCHL have anti-inflammatory activity and are used to treat rheumatoid arthritis, osteoarthritis and lupus. Although, CHL/HCHL have an anti-viral activity against several viruses in cell-cultures, the anti-viral activity in-vivo is questionable. Repurposing of CHL/HCHL to treat SARS-CoV-2 infection is appealing. However, there is empirical evidence from animal studies with other viruses suggesting that CHL/HCHL may have an untoward paradoxical effect. One thus cannot exclude the possibility that CHL may increase the severity of the disease and prove deleterious both for the patients and public health efforts to contain the highly contagious and explosive spread of SARS-CoV-2.

DOI: 10.1016/j.micinf.2020.04.004
PubMed: 32305500
PubMed Central: PMC7162740

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 001946
to stream Main, to step Curation: 001946

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Chloroquine paradox may cause more damage than help fight COVID-19.</title>
<author><name sortKey="Sharma, Anuj" sort="Sharma, Anuj" uniqKey="Sharma A" first="Anuj" last="Sharma">Anuj Sharma</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020 May - Jun</date>
<idno type="RBID">pubmed:32305500</idno>
<idno type="pmid">32305500</idno>
<idno type="doi">10.1016/j.micinf.2020.04.004</idno>
<idno type="pmc">PMC7162740</idno>
<idno type="wicri:Area/Main/Corpus">001946</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001946</idno>
<idno type="wicri:Area/Main/Curation">001946</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001946</idno>
<idno type="wicri:Area/Main/Exploration">001946</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Chloroquine paradox may cause more damage than help fight COVID-19.</title>
<author><name sortKey="Sharma, Anuj" sort="Sharma, Anuj" uniqKey="Sharma A" first="Anuj" last="Sharma">Anuj Sharma</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Microbes and infection</title>
<idno type="eISSN">1769-714X</idno>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antimalarials (adverse effects)</term>
<term>Antimalarials (therapeutic use)</term>
<term>Betacoronavirus (MeSH)</term>
<term>COVID-19 (MeSH)</term>
<term>Chloroquine (adverse effects)</term>
<term>Chloroquine (therapeutic use)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Humans (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>SARS-CoV-2 (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antipaludiques (effets indésirables)</term>
<term>Antipaludiques (usage thérapeutique)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Chloroquine (effets indésirables)</term>
<term>Chloroquine (usage thérapeutique)</term>
<term>Humains (MeSH)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antimalarials</term>
<term>Chloroquine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antimalarials</term>
<term>Chloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antipaludiques</term>
<term>Chloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antipaludiques</term>
<term>Chloroquine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term>
<term>COVID-19</term>
<term>Humans</term>
<term>Pandemics</term>
<term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Betacoronavirus</term>
<term>Humains</term>
<term>Pandémies</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Novel coronavirus disease 2019 (COVID-19) pandemic is the most recent health care crisis without specific prophylactic or therapeutic drugs. Antimalarial drug chloroquine (CHL) and its safer derivative hydroxychloroquine (HCHL) have been proposed to be repurposed to treat SARS coronavirus-2 (SARS-CoV-2), the causative agent of COVID-19. CHL/HCHL have anti-inflammatory activity and are used to treat rheumatoid arthritis, osteoarthritis and lupus. Although, CHL/HCHL have an anti-viral activity against several viruses in cell-cultures, the anti-viral activity in-vivo is questionable. Repurposing of CHL/HCHL to treat SARS-CoV-2 infection is appealing. However, there is empirical evidence from animal studies with other viruses suggesting that CHL/HCHL may have an untoward paradoxical effect. One thus cannot exclude the possibility that CHL may increase the severity of the disease and prove deleterious both for the patients and public health efforts to contain the highly contagious and explosive spread of SARS-CoV-2.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32305500</PMID>
<DateCompleted><Year>2020</Year>
<Month>06</Month>
<Day>30</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1769-714X</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>22</Volume>
<Issue>4-5</Issue>
<PubDate><MedlineDate>2020 May - Jun</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Microbes and infection</Title>
<ISOAbbreviation>Microbes Infect</ISOAbbreviation>
</Journal>
<ArticleTitle>Chloroquine paradox may cause more damage than help fight COVID-19.</ArticleTitle>
<Pagination><MedlinePgn>154-156</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S1286-4579(20)30071-X</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.micinf.2020.04.004</ELocationID>
<Abstract><AbstractText>Novel coronavirus disease 2019 (COVID-19) pandemic is the most recent health care crisis without specific prophylactic or therapeutic drugs. Antimalarial drug chloroquine (CHL) and its safer derivative hydroxychloroquine (HCHL) have been proposed to be repurposed to treat SARS coronavirus-2 (SARS-CoV-2), the causative agent of COVID-19. CHL/HCHL have anti-inflammatory activity and are used to treat rheumatoid arthritis, osteoarthritis and lupus. Although, CHL/HCHL have an anti-viral activity against several viruses in cell-cultures, the anti-viral activity in-vivo is questionable. Repurposing of CHL/HCHL to treat SARS-CoV-2 infection is appealing. However, there is empirical evidence from animal studies with other viruses suggesting that CHL/HCHL may have an untoward paradoxical effect. One thus cannot exclude the possibility that CHL may increase the severity of the disease and prove deleterious both for the patients and public health efforts to contain the highly contagious and explosive spread of SARS-CoV-2.</AbstractText>
<CopyrightInformation>Copyright © 2020 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sharma</LastName>
<ForeName>Anuj</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, United States of America.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>04</Month>
<Day>17</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>France</Country>
<MedlineTA>Microbes Infect</MedlineTA>
<NlmUniqueID>100883508</NlmUniqueID>
<ISSNLinking>1286-4579</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>886U3H6UFF</RegistryNumber>
<NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<CoiStatement>Declaration of Competing Interest Author declare no conflict of interest.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>03</Month>
<Day>31</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>04</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>04</Month>
<Day>13</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>4</Month>
<Day>20</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>7</Month>
<Day>1</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>4</Month>
<Day>20</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32305500</ArticleId>
<ArticleId IdType="pii">S1286-4579(20)30071-X</ArticleId>
<ArticleId IdType="doi">10.1016/j.micinf.2020.04.004</ArticleId>
<ArticleId IdType="pmc">PMC7162740</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Virol. 1991 Feb;65(2):992-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1846212</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Med. 1983 Jul 18;75(1A):11-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6408923</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Travel Med Infect Dis. 2020 Mar - Apr;34:101663</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32289548</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacol Ther. 1993 Feb-Mar;57(2-3):203-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8361993</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vector Borne Zoonotic Dis. 2008 Dec;8(6):837-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18620511</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clinics (Sao Paulo). 2013 May;68(5):621-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23778404</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Mal Infect. 2020 Jun;50(4):384</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32240719</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2009 Aug;53(8):3416-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19506054</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2011 Sep;11(9):677-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21550310</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Travel Med Infect Dis. 2020 Jul - Aug;36:101576</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32036012</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2009 Nov;83(22):11979-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19759137</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viruses. 2018 May 17;10(5):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29772762</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antivir Chem Chemother. 2006;17(5):275-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17176632</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 1986 Jun 5-11;321(6070):618-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3086747</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2020 May;177:104762</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32147496</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mem Inst Oswaldo Cruz. 2013 Aug;108(5):596-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23903975</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Negl Trop Dis. 2010 Aug 10;4(8):e785</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20706626</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2015 Dec;96(12):3484-3492</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26459826</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunol Lett. 1990 Aug;25(1-3):53-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2126528</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trends Immunol. 2019 Dec;40(12):1134-1148</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31735513</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Interferon Res. 1988 Apr;8(2):201-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3132512</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Trop Med Hyg. 1999 Aug;61(2):180-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10463664</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Inflammopharmacology. 2015 Oct;23(5):231-69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26246395</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):888-889</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32211771</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacol Res Perspect. 2017 Jan 23;5(1):e00293</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28596841</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Trop Med Hyg. 1985 Aug;88(4):261-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3910848</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Maryland</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Maryland"><name sortKey="Sharma, Anuj" sort="Sharma, Anuj" uniqKey="Sharma A" first="Anuj" last="Sharma">Anuj Sharma</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000848 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000848 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32305500
   |texte=   Chloroquine paradox may cause more damage than help fight COVID-19.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32305500" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Chloroquine paradox may cause more damage than help fight COVID-19.

Chloroquine paradox may cause more damage than help fight COVID-19.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki